drugset / Trial / NCT01134562
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
RandomizedSequentialTriple-blindTreatment
Summary
The purpose of this study is to characterize the safety and tolerability of single rising doses of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism.
Timeline
- Start
- 2010-09-07
- Primary completion
- 2011-04-02
- Completion
- 2011-04-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etelcalcetide | Other / unclassified | 5 mg | Intravenous |
| Subject | Etelcalcetide | Other / unclassified | 10 mg | Intravenous |
| Subject | Etelcalcetide | Other / unclassified | 20 mg | Intravenous |
| Subject | Etelcalcetide | Other / unclassified | 40 mg | Intravenous |
| Subject | Etelcalcetide | Other / unclassified | 60 mg | Intravenous |